These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8792794)

  • 1. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective.
    Petri M
    Scand J Rheumatol; 1996; 25(4):191-3. PubMed ID: 8792794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
    J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort.
    Petri M
    Lupus; 2010 Apr; 19(4):419-23. PubMed ID: 20353980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
    Somers E; Magder LS; Petri M
    J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
    Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
    Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardiolipin antibody.
    Greisman SG; Thayaparan RS; Godwin TA; Lockshin MD
    Arch Intern Med; 1991 Feb; 151(2):389-92. PubMed ID: 1992968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.
    Ho KT; Ahn CW; Alarcón GS; Baethge BA; Tan FK; Roseman J; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Calvo-Alén J; Reveille JD
    Rheumatology (Oxford); 2005 Oct; 44(10):1303-7. PubMed ID: 16030085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martínez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Rueda M; Aguirre C
    Lupus; 2004; 13(12):927-33. PubMed ID: 15645748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
    Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
    Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
    Sarzi-Puttini P; Atzeni F; Carrabba M
    Minerva Med; 2003 Apr; 94(2):63-70. PubMed ID: 12858154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martinez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Garmendia M; Gabriel Erdozain J; Villar I; Aguirre C
    Lupus; 2007; 16(10):810-6. PubMed ID: 17895304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.
    Love PE; Santoro SA
    Ann Intern Med; 1990 May; 112(9):682-98. PubMed ID: 2110431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies.
    Watanabe T; Oku K; Amengual O; Hisada R; Ohmura K; Nakagawa I; Shida H; Bohgaki T; Horita T; Yasuda S; Atsumi T
    Lupus; 2018 Feb; 27(2):225-234. PubMed ID: 28659045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.
    Brenner B; Tavori S; Lerner M; Tatarsky I; Lorber M
    Isr J Med Sci; 1992 Jan; 28(1):9-15. PubMed ID: 1733904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study.
    Berube C; Mitchell L; Silverman E; David M; Saint Cyr C; Laxer R; Adams M; Vegh P; Andrew M
    Pediatr Res; 1998 Sep; 44(3):351-6. PubMed ID: 9727712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus.
    Viard JP; Amoura Z; Bach JF
    Am J Med; 1992 Aug; 93(2):181-6. PubMed ID: 1497015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis.
    Wahl DG; Bounameaux H; de Moerloose P; Sarasin FP
    Arch Intern Med; 2000 Jul; 160(13):2042-8. PubMed ID: 10888978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
    Chen J; Sun S; Yan Q; Bao C; Fu Q
    Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.